Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Nereus Pharmaceuticals General Information
Nereus developed a pipeline of small molecule therapeutics derived from marine microorganisms. Its lead compounds included plinabulin (NPI‑2358), a vascular disrupting agent for solid tumors and HER2-negative breast cancer that later advanced to Phase 3 under BeyondSpring; salinosporamide A (NPI‑0052), a proteasome inhibitor for multiple myeloma and other cancers; and NPI‑1342/NPI‑1302a‑3 targeting the NF-kappa B pathway for oncology and inflammation. The company was acquired by Triphase Research & Development in 2012. Several programs were discontinued or outlicensed after acquisition.
Contact Information
Primary Industry
Biotech
Corporate Office
San Diego, California
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
University of California San Diego, BeyondSpring Pharmaceuticals
Nereus Pharmaceuticals Funding
No funding data available
To view Nereus Pharmaceuticals's complete valuation and funding history, request access »